| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From the Medizinische Klinik und Poliklinik D,* Experimentelle Nephrologie, the Institut für Physiologie II, the Klinik und Poliklinik für Urologie und Poliklinik für Allgemeine Chirurgie,¶ Universitätsklinikum Münster, Münster; the Institut für Anatomie und Zellbiologie, Universität Würzburg, Würzburg; and the Pharmazeutisches Institut,|| Klinische Pharmazie, Universität Bonn, Bonn, Germany
Cis-platin is an effective anti-neoplastic agent, but it is also highly nephrotoxic. Here, we clearly identify the human organic cation transporter 2 (hOCT2) as the critical transporter for cis-platin nephrotoxicity in isolated human proximal tubules and offer a potential mechanism for reducing nephrotoxicity in clinical practice. Interaction of cis-platin with hOCT2 in kidney or hOCT1 in liver was investigated with the fluorescent cation 4-[4-(dimethyl-amino)styril]-methylpyridinium in stably transfected HEK293 cells and for the first time in tissues physiologically expressing these transporters, human proximal tubules, and human hepatocyte couplets. Cis-platin (100 µmol/L) inhibited transport via hOCT2-HEK293 but not hOCT1-HEK293. In human proximal tubules cis-platin competed with basolateral organic cation transport, whereas it had no effect in tubules from a diabetic kidney or in hepatocytes. In hOCT2-HEK293 cells treated for 15 hours, incubation with cis-platin induced apoptosis, which was completely suppressed by contemporaneous incubation with the hOCT2 substrate cimetidine (100 µmol/L). These findings demonstrate that uptake of cis-platin is mediated by hOCT2 in renal proximal tubules, explaining its organ-specific toxicity. A combination of cis-platin with other substrates that compete for hOCT2 offers an effective option to decrease nephrotoxicity in the clinical setting.
This article has been cited by other articles:
 |
|
 |
|
  K. P. Kang, D. H. Kim, Y. J. Jung, A. S. Lee, S. Lee, S. Y. Lee, K. Y. Jang, M. J. Sung, S. K. Park, and W. Kim Alpha-lipoic acid attenuates cisplatin-induced acute kidney injury in mice by suppressing renal inflammation Nephrol. Dial. Transplant., May 27, 2009; (2009) gfp242v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Pabla, R. F. Murphy, K. Liu, and Z. Dong The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity Am J Physiol Renal Physiol, March 1, 2009; 296(3): F505 - F511. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Shnitsar, R. Eckardt, S. Gupta, J. Grottker, G. A. Muller, H. Koepsell, G. Burckhardt, and Y. Hagos Expression of Human Organic Cation Transporter 3 in Kidney Carcinoma Cell Lines Increases Chemosensitivity to Melphalan, Irinotecan, and Vincristine Cancer Res., February 15, 2009; 69(4): 1494 - 1501. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Ming, W. Ju, H. Wu, R. R. Tidwell, J. E. Hall, and D. R. Thakker Transport of Dicationic Drugs Pentamidine and Furamidine by Human Organic Cation Transporters Drug Metab. Dispos., February 1, 2009; 37(2): 424 - 430. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Yokoo, S. Masuda, A. Yonezawa, T. Terada, T. Katsura, and K.-i. Inui Significance of Organic Cation Transporter 3 (SLC22A3) Expression for the Cytotoxic Effect of Oxaliplatin in Colorectal Cancer Drug Metab. Dispos., November 1, 2008; 36(11): 2299 - 2306. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Okabe, G. Szakacs, M. A. Reimers, T. Suzuki, M. D. Hall, T. Abe, J. N. Weinstein, and M. M. Gottesman Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters Mol. Cancer Ther., September 1, 2008; 7(9): 3081 - 3091. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Aoki, T. Terada, M. Kajiwara, K. Ogasawara, I. Ikai, O. Ogawa, T. Katsura, and K.-i. Inui Kidney-specific expression of human organic cation transporter 2 (OCT2/SLC22A2) is regulated by DNA methylation Am J Physiol Renal Physiol, July 1, 2008; 295(1): F165 - F170. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Soodvilai, A. Chatsudthipong, and V. Chatsudthipong Role of MAPK and PKA in regulation of rbOCT2-mediated renal organic cation transport Am J Physiol Renal Physiol, July 1, 2007; 293(1): F21 - F27. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-i. Asaka, T. Terada, K. Ogasawara, T. Katsura, and K.-i. Inui Characterization of the Basal Promoter Element of Human Organic Cation Transporter 2 Gene J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 684 - 689. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Cristofori, E. Zanetti, D. Fregona, A. Piaia, and A. Trevisan Renal Proximal Tubule Segment-Specific Nephrotoxicity: An Overview on Biomarkers and Histopathology Toxicol Pathol, February 1, 2007; 35(2): 270 - 275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Yonezawa, S. Masuda, S. Yokoo, T. Katsura, and K.-i. Inui Cisplatin and Oxaliplatin, but Not Carboplatin and Nedaplatin, Are Substrates for Human Organic Cation Transporters (SLC22A1-3 and Multidrug and Toxin Extrusion Family) J. Pharmacol. Exp. Ther., November 1, 2006; 319(2): 879 - 886. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Zhang, K. S. Lovejoy, J. E. Shima, L. L. Lagpacan, Y. Shu, A. Lapuk, Y. Chen, T. Komori, J. W. Gray, X. Chen, et al. Organic Cation Transporters Are Determinants of Oxaliplatin Cytotoxicity. Cancer Res., September 1, 2006; 66(17): 8847 - 8857. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Biermann, D. Lang, V. Gorboulev, H. Koepsell, A. Sindic, R. Schroter, A. Zvirbliene, H. Pavenstadt, E. Schlatter, and G. Ciarimboli Characterization of regulatory mechanisms and states of human organic cation transporter 2 Am J Physiol Cell Physiol, June 1, 2006; 290(6): C1521 - C1531. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
